Defining psoriasis subtypes: features of severe psoriasis and associated diseases

References

• Christensen TE, Callis CP, Papenfuss J et al. Observations of psoriasis in the absence of therapeutic intervention identifies two unappreciated morphologic variants, thin-plaque and thick-plaque psoriasis, and their associated phenotypes. J. Invest. Dermatol.126, 2397–2403 (2006).
   PubMed Web of Science ®Google Scholar
• Christophers E, Mrowietz U. Psoriasis. In: Dermatology in General Medicine (5th Edition). Freedberg I, Eisen AZ, Wolff K et al. (Eds). McGraw-Hill, New York, NY, USA 495–521 (1999).
   Google Scholar
• Griffith CEM, Christophers E, Barker JNWN et al. A classification of psoriasis vulgaris according to phenotype. Br. J. Dermatol. (In press).
   Google Scholar
• Henseler T, Christophers E. Disease concomitance in psoriasis. J. Am. Acad. Dermatol.32, 98 (1995).
   Google Scholar
• Robinson D, Hackett M, Wong J, Kimball AB, Cohen R, Bala M: The IMID Study Group. Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001–2002. Curr. Med. Res. Opin.22, 989–1000 (2006).
   PubMed Web of Science ®Google Scholar
• Sheehan NJ. The ramifications of HLA-B27. J. Roy. Soc. Med.97, 10–18 (2004).
   PubMed Web of Science ®Google Scholar
• Lee FI, Bellarys SV, Francis C. Increased occurrence of psoriasis in patients with Crohn’s disease and their relatives. Am. J. Gastroenterol.85, 962–963 (1991).
   Google Scholar
• Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology129, 827–836 (2005).
   PubMed Web of Science ®Google Scholar
• Christophers E. Comorbidities in psoriasis. Eur. J. Acad. Dermatol.20, 52–55 (2006).
   Web of Science ®Google Scholar
• Sterry W, Barker J, Boehncke WH et al. Biological therapies in the systemic management of psoriasis: an international consensus conference. Br. J. Dermatol.151(Suppl. 69), 3–17 (2004)
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a Phase III, multicentre, double-blind trial. Lancet366, 1367–1374 (2005).
   PubMed Web of Science ®Google Scholar
• Sattar N, McInnes I. Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr. Opin. Rheumatol.17, 286–292 (2005).
   PubMed Web of Science ®Google Scholar
• Dessein PH, Joffe BI, Veller MG et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J. Rheumatol.32, 435–442 (2005).
   PubMed Web of Science ®Google Scholar
• Wallenberg-Jonsson S, Johansson H, Öhman ML, Rantapää-Dahlquist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: a retrospective cohort study from disease onset. J. Rheumatol.26, 2562–2571 (1999).
   Google Scholar
• Dessein PH, Joffe BI, Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res. Ther.7, R634–R643 (2005).
   PubMed Web of Science ®Google Scholar
• Wong M, Toh L, Wilson A et al. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum.48, 81–89 (2003).
   PubMed Web of Science ®Google Scholar
• Dessein PH, Stanwix AE, Joffe BI. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin resistence and high-densitiy lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res.4, R5 (2002).
   PubMedGoogle Scholar
• Jacobson LT, Turesson C, Gulfe A et al. Treatment with tumor necrosis blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol.32, 1213–1218 (2005).
   Google Scholar
• Geborek P. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular event in patients with rheumatoid arthritis. J. Rheumatol.32, 1213–1218 (2005).
   Google Scholar
• Ho P, Bruce IN, Symmons D et al. Anti-tumor necrosis factor-α treatment improves endothelial function inpatients with rheumatoid arthritis. Circulation106, 2184–2187 (2002).
   Google Scholar
• Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica172, 298–304 (1986).
   PubMedGoogle Scholar
• Naldi L, Parazzini F, Brevi A et al. Family history, smoking habits, alcohol consumption and risk of psoriasis. Br. J. Dermatol.127, 212–217 (1991).
   Google Scholar
• McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br. J. Dermatol.99, 469–475 (1978).
   PubMed Web of Science ®Google Scholar
• Mallbris L, Akre O, Granath F et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not outpatients. Eur. J. Epidemiol.19, 225–230 (2004).
   PubMed Web of Science ®Google Scholar
• Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch. Dermatol. Res.298(7), 921–328 (2006).
   Google Scholar